In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Celleron Therapeutics Ltd.

Latest From Celleron Therapeutics Ltd.

Finance Watch: Global Ventures Step Into The Spotlight As The US Takes A Breather

Private Company Edition: I-Mab's $220m Series C round continued the trend of big investments in companies focused on or headquartered in China. Also, Shanghai-based Nuance brought in a combined $35m and European firms dominated recent small financings as US VC deals took a summer break.

Financing StartUps and SMEs

Enteric Fever, Plague Vaccines From Synthetic Biology Firm Near Clinical Studies

The oral administration of synthetic thermostable vaccines that use a bacterial vector could enter clinical studies in 2019, funded by VCs interested in their use in emerging markets, where endemic and childhood diseases could yield to the new approach.

Financing Vaccines

Quintiles invests in biomarker start-up; Glyn Edwards to head

Quintiles has invested £3 million in a new company formed in partnership with the University of Oxford and two of its professors, which will provide oncology consulting services and new cancer biomarkers to clients.


Flexion Exploits Big Pharma as Discovery Supplier

Big Pharma, unable to exploit its own research productivity, is increasingly seeing itself as a supplier of discovery assets. That's bad news for discovery-based biotech, but good news for companies with a talent for faster, more predictable development capabilities. Since its formation in the fall of 2007, Flexion Therapeutics has apparently had no trouble getting Big Pharmas to let them review their shelved compounds, 130 or so of them from eight to 10 companies. Flexion, built around Lilly's fast-to-proof-of-concept strategy, is attempting to take advantage of the trend; it's in-licensed five products from three Big Pharmas.
BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Celleron Therapeutics Ltd.
  • Senior Management
  • Nick La Thangue, PhD, CEO
    Bill Fleming, CFO
    David Kerr, CMO
    John Whittaker, PhD, COO
  • Contact Info
  • Celleron Therapeutics Ltd.
    Phone: (44)
    Magdalene Ctr., Oxford Science Park
    Robert Robinson
    Oxford, OX4 4GA